471 related articles for article (PubMed ID: 33778026)
1. The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study.
Wang J; Lu Y; Min X; Yuan T; Wei J; Cai Z
Front Cardiovasc Med; 2021; 8():648212. PubMed ID: 33778026
[No Abstract] [Full Text] [Related]
2. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension.
Gu J; Yin ZF; Zhang JF; Wang CQ
Int J Cardiol; 2020 May; 306():140-145. PubMed ID: 31711850
[TBL] [Abstract][Full Text] [Related]
3. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M; Friberg L
JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study.
Su Y; Ma M; Zhang H; Pan X; Zhang X; Zhang F; Lv Y; Yan C
Exp Ther Med; 2020 Nov; 20(5):101. PubMed ID: 32973950
[TBL] [Abstract][Full Text] [Related]
6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
8. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.
Retwiński A; Kosmalski M; Crespo-Leiro M; Maggioni A; Opolski G; Ponikowski P; Poloński L; Jankowska E; Drzewoski J; Drożdż J
Kardiol Pol; 2018; 76(9):1336-1343. PubMed ID: 29862487
[TBL] [Abstract][Full Text] [Related]
9. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
[TBL] [Abstract][Full Text] [Related]
10. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
[TBL] [Abstract][Full Text] [Related]
12. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry.
Carrasco-Sánchez FJ; Gomez-Huelgas R; Formiga F; Conde-Martel A; Trullàs JC; Bettencourt P; Arévalo-Lorido JC; Pérez-Barquero MM;
Diabetes Res Clin Pract; 2014 Jun; 104(3):410-9. PubMed ID: 24768593
[TBL] [Abstract][Full Text] [Related]
13. Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction: results of the Japanese heart failure syndrome with preserved ejection fraction registry.
Okuno K; Naito Y; Asakura M; Sugahara M; Ando T; Yasumura S; Nagai T; Saito Y; Yoshikawa T; Masuyama T; Anzai T
Heart Vessels; 2019 Jul; 34(7):1168-1177. PubMed ID: 30675647
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
[TBL] [Abstract][Full Text] [Related]
15. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Kao DP; Lewsey JD; Anand IS; Massie BM; Zile MR; Carson PE; McKelvie RS; Komajda M; McMurray JJ; Lindenfeld J
Eur J Heart Fail; 2015 Sep; 17(9):925-35. PubMed ID: 26250359
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
Pandey A; Golwala H; Sheng S; DeVore AD; Hernandez AF; Bhatt DL; Heidenreich PA; Yancy CW; de Lemos JA; Fonarow GC
JAMA Cardiol; 2017 Feb; 2(2):136-145. PubMed ID: 28030747
[TBL] [Abstract][Full Text] [Related]
17. Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation.
Machino-Ohtsuka T; Seo Y; Ishizu T; Yamamoto M; Hamada-Harimura Y; Machino T; Yamasaki H; Sekiguchi Y; Nogami A; Aonuma K; Ieda M
J Cardiol; 2019 Sep; 74(3):235-244. PubMed ID: 30910388
[TBL] [Abstract][Full Text] [Related]
18. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
19. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
